Chris Poulios, Steering Committee Member of Young Cancer Professionals at the European Cancer Organisation, shared a post on LinkedIn:
“ADCs from Paolo Tarantino, a leading expert in the field, at ASCO26 who stressed that to optimally use ADCs new biomarkers are required!
Pathology is here to assist with optimising IHC, implementing multiplex-IHC and -IF, and also with AI and spatial-omics!
The next part of the session confirmed exactly this!
Immediate next 2 lectures by Drs Italiano Antoine and Gil Shamai offered an insight for the new tools that are getting into use: multiplex IHC/IF and AI!
Special comment for Dr Shamai who demonstrated that the AI analysis of a histopathology image may be more accurate than molecular analysis as the presence of a gene alteration does not always correlate with protein expression and thus patient benefit from a targeted treatment like ADCs!
We have the tools to make the big leap forward for cancer care! My thanks to all involved in these panels and to American Society of Clinical Oncology (ASCO) for enabling this session!”
Other articles featuring Dr. Poulios on OncoDaily.
